All
Old therapy offers new hope for skin disease
February 1st 2005Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.
AD treatments exhibit long-term relief for other inflammatory skin conditions
February 1st 2005The efficacy and remarkable safety profile of two drugs, tacrolimus (Protopic?, Fujisawa Healthcare) and pimecrolimus (Elidel?, Novartis), have revolutionized the treatment of atopic dermatitis (AD) and appear to have promise for a variety of other inflammatory skin conditions that require long-term therapy, according to Alan Fleischer, M.D., professor and chair of dermatology at Wake Forest University School of Medicine.
How to optimize radiofrequency treatment results
February 1st 2005Lake Buena Vista, Fla. - David Goldberg, M.D., says that for prospective cosmetic surgery patients wishing to quickly but effectively tighten facial wrinkles, radiofrequency (RF) rejuvenation - particularly with the ThermaCool ?TC machine developed by Thermage ?, which won federal approval as a full-face treatment last July - may be the way to go.
Storm swirls over drug imports
February 1st 2005National report — With many prescription drugs costing at least twice as much domestically as they do internationally, it's no surprise that patients seek foreign sources for everything from cholesterol killers to dermal fillers. Nor is it surprising that many such purchases can imperil patients' health.
Fat deposit, cellulite tx options
February 1st 2005Miami Beach, Fla. — New information regarding the treatment of fat and cellulite gives dermatologists something to consider as an option to traditional treatments. According to Doris M. Hexsel, M.D., the new research and clinical experience she presented at the H&H Dermatology Seminar are crucial to decisions about incorporating any new treatment method.
Multiple facial papules? Consider Birt-Hogg-Dub?
February 1st 2005Newport Beach, Calif. — When a patient presents with multiple facial papules, consider the rare but potentially fatal condition known as Birt-Hogg-Dub? syndrome, says Melvin W. Chiu, M.D., who spoke at the annual meeting of the Pacific Dermatologic Association.
Rosacea treatment studies scrutinized by reviewers
February 1st 2005Leiden, The Netherlands — Cochrane reviewers evaluating published studies of interventions for rosacea concluded there is sufficient evidence demonstrating the efficacy and safety of topical metronidazole and azelaic acid cream used short-term. However, as another important outcome, their analyses also highlighted the need for better-quality studies evaluating treatments for rosacea.
Desloratadine ameliorates QOL burden of CIU
February 1st 2005Toronto — The nonsedating, selective H1-receptor antagonist desloratadine improves signs and symptoms of chronic idiopathic urticaria (CIU), but also has a positive effect on quality of life (QOL) for affected patients, according to Charles W. Lynde, M.D.
Old therapy offers new hope for skin disease
February 1st 2005Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.
Novel cephalosporin fights MRSA
February 1st 2005Washington — Promising results were seen in a phase 2 trial of the first drug in a new class of cephalosporins active against multi-drug resistant Staphlococcus aureus, according to Markus Heep, M.D., medical microbiologist and project physician at Basilea Pharmaceutica, Ltd. in Basel, Switzerland.
Biologics signal new psoriasis strategies
February 1st 2005Singapore — Recent clinical experience with biologic response modifiers suggests that chronic plaque psoriasis may not be represented by a single disease, but by several, and treating it effectively could require combinations of older and newer therapies.